Health care billing claims data have been widely used to study health care use, spending and policy changes. In this interactive talk, drawing upon our experience in working with OptumInsight claims database, we first discuss a case study of how non-clinical factors are associated with anticoagulation receipt among enrollees with cancer associated thrombosis (CAT), which is a leading cause of death among patients with cancer. In particular, we conducted a retrospective cohort study of Optum’s de-identified Clinformatics Database of adults with cancer diagnosed between 2009 and 2016 who developed CAT, treated with an outpatient anticoagulant (warfarin, low molecular weight heparin (LMWH), or a direct oral anticoagulant (DOAC)). Of 12,622 patients, three months after an episode of CAT, 1,485 (12%) were on LMWH, 1,546 (12%) on DOACs, and 9,591 (76%) were on warfarin. When controlling for other factors, anticoagulant use was significantly associated with socioeconomic factors, region, comorbidities, type of thrombosis, and cancer subtype. A second part of the talk will discuss issues concerning data quality, preprocessing, selection bias and reproducibility. We also discuss the potential and pitfalls of health care claims data in relation to other data sources, such as electronic health records and/or biobanks.
Xu Shi, shixu@umich.eduHealth Care Claims Data for Health Services Research: A Case Study in Cancer Associated Thrombosis
Dr. Zhenke Wu and Mengbing Li
January 25, 2021
12:00 pm - 1:00 pm
Online in Zoom
Contact Information: Xu Shi, shixu@umich.edu
Counts towards DEI continuing professional education
Health care billing claims data have been widely used to study health care use, spending and policy changes. In this interactive talk, drawing upon our experience in working with OptumInsight claims database, we first discuss a case study of how non-clinical factors are associated with anticoagulation receipt among enrollees with cancer associated thrombosis (CAT), which is a leading cause of death among patients with cancer. In particular, we conducted a retrospective cohort study of Optum’s de-identified Clinformatics Database of adults with cancer diagnosed between 2009 and 2016 who developed CAT, treated with an outpatient anticoagulant (warfarin, low molecular weight heparin (LMWH), or a direct oral anticoagulant (DOAC)). Of 12,622 patients, three months after an episode of CAT, 1,485 (12%) were on LMWH, 1,546 (12%) on DOACs, and 9,591 (76%) were on warfarin. When controlling for other factors, anticoagulant use was significantly associated with socioeconomic factors, region, comorbidities, type of thrombosis, and cancer subtype. A second part of the talk will discuss issues concerning data quality, preprocessing, selection bias and reproducibility. We also discuss the potential and pitfalls of health care claims data in relation to other data sources, such as electronic health records and/or biobanks.